A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

• Conditions: Ocular Hypertension; Open-angle Glaucoma
• Interventions: Drug: Travoprost (TRAVATAN); Drug: Travoprost, Investigational

• Registration Number: NCT00293761
• Lead Sponsor: Alcon Research

Brief Summary

The purpose of the study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension

Detailed Description

Not available

Study Timeline

• Study Start: 2006-01
• Study First Submitted: 2006-02-17
• Study First Submitted QC: 2006-02-17
• Study First Posted: 2006-02-20
• Primary Completion: 2006-05
• Study Completion: 2006-05
• Status Verified: 2012-03
• Last Update Submitted: 2016-11-17
• Last Update Posted: 2016-11-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 109

Inclusion Criteria

• Adult patients of either sex of any race diagnosed with open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component) or ocular hypertension.
• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria

• Under age 18.
• Other protocol-defined exclusion criteria may apply.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Travatan	Travoprost (TRAVATAN)	-
Travatan, Investigational	Travoprost, Investigational	-

Primary Outcome Measures

Name	Time	Method
Mean IOP